In the last decades, defibrillator therapy has revolutionized treatment of patients at risk for sudden cardiac death. Multiple clinical trials have shown the benefit of implantable cardioverter–defibrillators (ICD) for primary and secondary prevention of sudden cardiac death. Being an entirely subcutaneous system, the S-ICD avoids important periprocedural and long-term complications associated with transvenous implantable cardioverter–defibrillator (TV-ICD) systems.

Cardiac contractility modulation (CCM) is a device-based heart failure therapy with 3 intracardiac leads that enhances contractile strength of the myocardium independent of the synchrony of myocardial contraction. CCM signals are non-excitatory high voltage electrical impulses that are applied during the absolute refractory period. CCM has been proven to improve Quality of Life, exercise capacity and left ventricular parameters and might decrease mortality.

In this unique and interactive workshop a detailed and stepwise instruction will be offered on implantation technique of S-ICD and CCM systems including life-videos, case reports, voting questions and an approach for the concomitant implantation of both systems. A special section will be dedicated to adequate patient selection for both systems and future developments will be discussed.

Biography
Juergen Kuschyk has completed his Medical Degree at the University of Münster, Germany. He is the Director of Device Therapy at the University Medical Center Mannheim, Germany. He is Senior Consultant in Cardiology-Electrophysiology. He has published more than 100 papers in reputed journals and has been serving as an Editorial Board Member of repute. He is international proctor for S-ICD and CCM. From 2000-2015 he gave >200 international presentations on device therapy. His main clinical research includes: Device therapy for prevention of sudden cardiac death and chronic heart failure.